Created Micro strategy and added Noxopharm (NOX.AX)

Product

  • Drug (NOX66) that sensitizes cancer cells to radiotherapy and chemotherapy
    • Makes chemotherapy >2000x stronger
    • Makes radiotherapy 10x stronger
    • No affect on healthy cells
  • Originally developed in 2009 but had a half-life of 40min
  • CEO, after being diagnosed with metastatic cancer, developed Liprose delivery mechanism to increase half-life to 12 hours and allow the drug to cross the blood brain barrier
  • Successfully cured one metastatic cancer patient to date (the CEO)

Strategy

Key takeaway is that the founders expect to know whether the product will be a success by the end of 2017 (Phase 1).

Risks

  • CEO dies (he’s over 60)
  • Unable to raise the necessary funds for clinical trials

nox timeline.PNG

nox ip.PNG

nox takeaway.PNG

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s